drugset
drugset / Trial / NCT01650129

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

NCT01650129 ↗

Phase 3 Completed 83 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of biphasic insulin aspart (BIAsp) 50 (NN-X14Mix50) compared with biphasic human insulin (BHI) 50 in subjects with type 2 diabetes.

Timeline

Start
2000-12-13
Primary completion
2001-10-18
Completion
2001-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic — Subcutaneous
Subject insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus